Immuron achieves record quarterly travelan® sales

Highlights: record quarterly travelan® sales of $1,550,240 total sales of a$1,565,767 in q1, fy24 $1,508,933 increase on q1, fy23 sales 130% higher than pre-pandemic period q1, fy20 sales melbourne, australia, oct. 11, 2023 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), an australian based and globally integrated biopharmaceutical company is pleased to announce record quarterly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune supplement travelan®. australia immuron previously reported (august 9, 2023) that short term stock outages of travelan® in some wholesalers and pharmacies in the june 2023 quarter was resolved following receipt of gmp clearance from the therapeutic goods administration (tga).
IMRN Ratings Summary
IMRN Quant Ranking